1 |
Jassal SV, Roscoe JM, Zaltzman JS, Mazzulli T, Krajden M, Gadawski M. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998;9:1697-708.
|
2 |
Zylber-Katz E, Granot E. Abrupt increase of Tacrolimus blood levels during an episode of Shigella infection in a child after liver transplantation. Ther Drug Monit 2001;23: 647-9.
DOI
ScienceOn
|
3 |
Hochleitner BW, Bosmuller C, Nehoda H, Fruhwirt M, Simma B, Ellemunter H, et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001;14:230-3.
DOI
ScienceOn
|
4 |
Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001;33:E62-8.
DOI
|
5 |
Snydman DR, Werner BG, Heinze-Lacey B, Veradi VP, Tilner NL. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 1987;317:1049-54.
DOI
ScienceOn
|
6 |
Tanaka Y, Kanda Y, Kami M, Mori S, Amaki T, Kusumi E, et al. Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;30:315-9.
DOI
ScienceOn
|
7 |
Griscelli F, Barrois M, Chauvin S, Lastere S, Bellet D, Bourhis JH. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipient by real-time PCR. J Clin Microbiol 2001;39:4362-9.
DOI
ScienceOn
|
8 |
Fisher L, Rautenberg P, Bienengrabe H, Leimenstoll G. Antigenemia, immunoblotting, and enzyme immunoassay for early diagnosis of cytomegalovirus infection in renal transplant patients. Transpl Int 1993;6:201-5.
DOI
ScienceOn
|
9 |
Komorowski RA, Cohen EB, Kauffman HM, Adams MB. Gastrointestinal complications in renal transplant recipients. Am J Clin Pathol 1986;86:161-7.
DOI
|
10 |
Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadavaric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998;65:1450-4.
DOI
ScienceOn
|
11 |
Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000;14:136-8.
DOI
ScienceOn
|
12 |
ter Meulen CG, Wetzels JFM, Hilbrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000;15:711-4.
DOI
|
13 |
Abbott KC, Hypolite IO, Viola R, Poropatich RK, Hshieh P, Cruess D, et al. Hospitalization for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 2002;12:402-9.
DOI
ScienceOn
|
14 |
Pouteil-Noble C, Ecochard R, Landrivon G, Donia-Maged A, Tardy JC, Bosshard S, et al. Cytomegalovirus infection-an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993;55:851-7.
DOI
ScienceOn
|
15 |
Bock GH, Sullivan EK, Miller D, Gimon D, Alexander S, Eloois E, et al. Cytomegalovirus infections following renal transplantation-effects of antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatric Nephrol 1997;11:665-71.
DOI
ScienceOn
|
16 |
Robinson LG, Hilinski J, Graham F, Hymes L, Beck-Sague CM, Hsia J, et al. Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation. Pediatr Transplant 2002;6: 111-8.
DOI
ScienceOn
|
17 |
Wolf DG, Spector SA. Early diagnosis of human cytomegalovirus disease in transplant recipient by DNA amplification in plasma. Transplantation 1993;56:330-4.
DOI
ScienceOn
|